Aviir Obtains $30,000,000 New Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c0cd07f3-76ed-4091-9dd7-caf3bdf5dbe2&Preview=1 -
Date
12/20/2011 -
Company Name
Aviir -
Mailing Address
2463 Faber Place Palo Alto, CA 94303 -
Company Description
Aviir is a venture-funded biotechnology company developing cutting-edge, convenient diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology draws on years of research at Stanford University, and combines the scientific founders’ deep understanding of disease marker proteins and advanced biostatistics. Aviir is pursuing an aggressive commercialization strategy, with initial products expected to reach the market in 2008. -
Website
http://www.aviir.com -
Transaction Type
Venture Equity -
Transaction Amount
$30,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
The proceeds will be used to fund commercialization of TruRisk(TM), Aviir’s proprietary cardiac risk assessment technology, and additional molecular testing services provided through Aviir Heart Laboratories, based in Irvine, California. -
M&A Terms
-
Venture Investor
Merck Capital Ventures -
Venture Investor
Bay City Capital -
Venture Investor
New Leaf Venture Partners -
Venture Investor
Aberdare Ventures
